GlassScriptPhysician profile
Rodolfo W Guzman
NPI 1205867835
$6,929.10
in general payments reported to CMS, 2019-2025
30 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $929 · 2021: $1,168 · 2022: $1,342 · 2023: $836 · 2024: $585 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,776.30 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $773.44 | 2019-2024 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $684.90 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $558.17 | 2021-2025 | |
| Lilly USA, LLC | $467.95 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Horizon Therapeutics Plc | $329.68 | 2021-2023 | Tepezza |
| Amarin Pharma, INC. | $324.71 | 2019-2022 | |
| Abbvie INC. | $258.30 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $177.45 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $159.40 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $142.16 | 2023-2025 | Yorvipath |
| Dexcom, INC. | $137.54 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.21 | 2019-2022 | |
| Medtronic, INC. | $123.06 | 2021-2022 | |
| Allergan, INC. | $112.46 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $109.41 | 2020-2025 | Tepezza, Repatha |
| Novartis Pharmaceuticals Corporation | $106.48 | 2021-2022 | |
| Abbott Laboratories | $105.03 | 2021-2023 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $96.81 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.21 | 2020-2021 | |
| Vifor Pharma, INC. | $52.43 | 2022-2025 | Veltassa |
| Xeris Pharmaceuticals, INC. | $47.76 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Esperion Therapeutics, INC. | $44.17 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $24.61 | 2021 | |
| Recordati_rare_diseases_inc. | $23.60 | 2024 | Signifor Lar, Isturisa |
| Madrigal Pharmaceuticals | $23.03 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $21.63 | 2023 | Veozah |
| Becton, Dickinson and Company | $19.16 | 2021 | |
| Althera Pharmaceuticals LLC | $18.38 | 2021 | |
| Intra-Sana Laboratories | $17.66 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodolfo Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.